Abbott Molecular Flu, Strep Tests Get FDA Clearance

NEW YORK (GenomeWeb) – Abbott said today that the US Food and Drug Administration has cleared its next-generation Influenza A & B 2 and Strep A 2 molecular assays for point-of-care testing. The new assays enable fast time-to-results for molecular influenza A & B and Strep A testing at the point of care, the firm said.